Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10551930		
Filing Date		2005-10-03		
First Named Inventor	Lui, Kevin			
Art Unit		1614		
Examiner Name				
Attorney Docket Number		K0002-502US		

				U.S.	PATENTS		Remove	
Examiner Initial*	xaminer Cite Patent Number Nind Issue Date Name of Patentee of Applicant Releva			Columns, nt Passaç s Appear	Lines where ges or Relevant			
	1							
If you wisl	h to a	dd additional U.S. Paten	t citatio	n information pl	ease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Releva		Lines where ges or Relevant
	1	20060167012	A1	2006-07-27	Stewart A. Noble et al			
	2	20060205736	A1	2006-09-14	Stewart A. Noble et al			
	3	20050070532	A1	2005-03-31	Kevin Liu			
	4	20050203151	A1	2005-09-15	James W. Malecha			
	5	20050234046	A1	2005-10-20	Cuxiang Zhao			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10551930	
iling Date		2005-10-03	
irst Named Inventor	Lui, Kevin		
Art Unit		1614	
xaminer Name			
Manager David Month	nr.	KUUUS EUSTIS	

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	where Relevant Passages or Relevant Figures Appear	тя
	1	03024395	wo	A2	2003-03-27	TULARIK INC.		
If you wis	h to a	d additional Foreign P	atent Document	citation	information pl	ease click the Add button	Add	
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc), o	the article (when appropriate, pages(s), volume-is		Тŝ
	1	STEPHAN D. PARENT, Modulators of PPAR and				er 23, 2006 (not yet publish	ed) Entitled: Salts of	
	2 KEVIN LIU, Application No.: 19552.258, Flact. October 3, 2005 (not yet published) Entitled. N-Containing Heteroeromatic Compounds As Modulators of PPARs and Methods of Treating Metabolic Disorders							
	3 STEWART A. NOBLE, Application No.: 60/800,905 (not yet published) Entitled: Sulfonyi-Substituted Bicyclic Compounds As Modulators of PPAR							
	4 KALYPSYS, INC., Application No: PCTUS2006040075 (not yet published) Entitled: Sulfonyi-Substituted Anyl Compounds As Modulators of Peroxesome Profilerator Activated Receptors.							
	5 KALYPSYS, INC., Application No.: PCTUS2008040079 (not yet published) Entitled: Novel Compounds As Modulators of PPAR							
	6	TIMOTHY M. WILLSON February 24, 2000, Col-		om Orph	an Receptors to	Drug Discovery", Journal o	of Medicinal Chemistry,	
If you wie	h to a	td additional non nator	et litoraturo docu	mont cit	ation informat	ion places click the Add I	hutton Add	

EXAMINER SIGNATURE							
Examiner Signature		Date Considered					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

16e Kin Codes of USPTO Patert Documents at www.USPTO.GOV or MPEP 801.04. 2 Enter office that issued the document, by the hoveletic rode (WIPO Standard S13.) 3 "For implance patent for comments, the included on the year of the import norm precede the serial rode plasted document, and occurrently the appropriate symbols as indicated on the document under WIPO Standard S1.16 if possible. 9 Applicant is to place a check mark here if English languages translation to statistics.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10551930
	Filing Date		2005-10-03
	First Named Inventor	Lui, K	evin
	Art Unit		1614
	Examiner Name		
Attorney Docket Number		er	K0002-502US

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.9	8 to make the	appropria	ite selection(s):
---------------	----------	---------	---------------	-----------	-------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

-

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Raymond J. Ho/	Date (YYYY-MM-DD)	2007-04-16
Name/Print	Raymond J. Ho	Registration Number	41838

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.